← Back to Search

PET/CT Imaging for Heart Function in Lung Cancer

N/A

Recruiting

Led By Yevgeniy Vinogradskiy

Research Sponsored by Thomas Jefferson University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 30 months after radiotherapy

Awards & highlights

Study Summary

This trial studies if PET/CT scans can help detect changes in heart function due to radiation therapy in lung cancer patients.

Who is the study for?

This trial is for adults with pathologically confirmed lung cancer who are about to undergo radiation therapy and have a life expectancy of at least 3 months. They must consent to the study's procedures, be available throughout, and receive a heart dose of radiation estimated at 5 Gy or more. It excludes those on palliative radiation doses or with contraindications for FDG PET-CT scans.Check my eligibility

What is being tested?

The EUCLID Trial is testing the use of PET/CT imaging to detect potential cardiac damage from radiation treatment in lung cancer patients. The goal is to monitor heart function before, during, and after radiotherapy using this imaging technique which can highlight inflammation and tissue viability.See study design

What are the potential side effects?

Since this trial involves diagnostic imaging rather than medication, side effects are minimal but may include discomfort from lying still during the scan or reactions related to contrast agents used in PET/CT such as allergic reactions or metallic taste.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 30 months after radiotherapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 30 months after radiotherapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 months after radiotherapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in mean standardized uptake value (SUV) changes in the heart

Secondary outcome measures

Ability of pre- to post-radiotherapy SUV changes in the heart

Cardiac related death

Cardiac toxicity

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (sarcoidosis FDG PET-CT)Experimental Treatment4 Interventions

Patients undergo sarcoidosis FDG PET-CT of the heart before, during and, after radiotherapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Positron Emission Tomography

2008

Completed Phase 2

~2240

Computed Tomography

2017

Completed Phase 2

~2720

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor

445 Previous Clinical Trials

145,469 Total Patients Enrolled

Yevgeniy VinogradskiyPrincipal InvestigatorThomas Jefferson University

Media Library

Diagnostic (sarcoidosis FDG PET-CT) Clinical Trial Eligibility Overview. Trial Name: NCT05775939 — N/A

Esophageal Cancer Research Study Groups: Diagnostic (sarcoidosis FDG PET-CT)

Esophageal Cancer Clinical Trial 2023: Diagnostic (sarcoidosis FDG PET-CT) Highlights & Side Effects. Trial Name: NCT05775939 — N/A

Diagnostic (sarcoidosis FDG PET-CT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05775939 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment size of this clinical trial?

"Affirmative. The clinicaltrials.gov website lists this trial as actively recruiting with a starting date of January 20th, 2022 and an update on March 7th, 2023. It is looking to admit twenty individuals across one research site."

Answered by AI

Are there any opportunities for participants to join this experiment now?

"Affirmative, clinicaltrials.gov reports that this medical trial is actively recruiting patients and was initially posted on January 20th 2023 before the most recent edit made on March 7th of the same year. The research requires recruitment of a total of twenty individuals from one location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

2023. "PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05775939.

All > Esophageal Cancer